Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)

Bengt I. Eriksson; Giancarlo Agnelli; Alexander S. Gallus; Michael R. Lassen; Martin H. Prins; Ronny W. Renfurm; Makoto Kashiwa; Alexander G. G. Turpie

doi:10.1160/TH13-04-0296

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 111(02): 213-225
DOI: 10.1160/TH13-04-0296

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)

Bengt I. Eriksson

¹Sahlgrenska University Hospital, Gothenburg, Sweden

,

Giancarlo Agnelli

²University of Perugia, Perugia, Italy

,

Alexander S. Gallus

³Flinders Medical Centre, Adelaide, Australia

,

Michael R. Lassen

⁴Spine Center Copenhagen, Copenhagen University Hospital, Glostrup, Denmark

,

Martin H. Prins

⁵University of Maastricht, Maastricht, The Netherlands

,

Ronny W. Renfurm

⁶Astellas Pharma Global Development Europe, Leiden, The Netherlands

⁷Department of Cardiology C5-P, Leiden University Medical Center, Leiden, The Netherlands

,

Makoto Kashiwa

⁸Astellas Pharma Inc, Tokyo, Japan

,

Alexander G. G. Turpie

⁹Hamilton General Hospital, Hamilton, Canada

› Institutsangaben

Abstract

Summary

This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty. Patients, investigators, pharmacists and sponsor were all blinded to treatment allocation. Darexaban administration started 6-10 hours (h) post-surgery. Enoxaparin 40 mg qd administration started 12 ± 2 h before surgery. Treatment continued for 35 days. Bilateral venography was performed on Day 10 ± 2. The primary efficacy outcome was total VTEs (composite of proximal/distal deep-vein thrombosis, pulmonary embolism) or death, at Day 12. Total VTE rates were similar across all groups. There was no apparent difference in efficacy between onceand twice-daily darexaban (odds ratio [OR] 1.00; 95% confidence interval [CI] 0.71–1.42; p=0.988), or total daily dose (30 mg/day vs 60 mg/day; OR 0.81; 95% CI 0.57–1.15; p=0.244). There was no significant difference in major and/or clinically relevant non-major bleeding between darexaban qd or bid, or between total daily doses of 30 mg or 60 mg, and also for any dosing regimen of darexaban vs enoxaparin. Darexaban was well tolerated, without signs of liver toxicity. In conclusion, darexaban, administered qd or bid, and at total daily doses of 30 mg or 60 mg, appears to be effective for VTE prevention and was well tolerated. Data suggest no significant differences between a once- or twice-daily dosing regimen.

Keywords

Darexaban - enoxaparin - orthopaedic surgery - venous thromboembolism - bleeding

Volltext

Referenzen

References
1 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8th Edition) Chest 2008; 133 (Suppl. 06) 381S-453S.
2 National Collaborating Centre for Acute and Chronic Conditions.. Venous thromboembolism: reducing the risk. Reducing the risk of venous thromboem-bolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital (Clinical guideline no. 92). London (UK): National Institute for Health and Clinical Excellence (NICE); 2010
3 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 338S-400S.
4 Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 2010; 70: 2153-2170.
5 Lee YK, Player MR. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Med Res Reviews 2011; 31: 202-283.
6 Herault JP, Bernat A, Pflieger AM. et al. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Therap 1997; 283: 16-22.
7 Eikelboom JW, Weitz JI. A replacement for warfarin: the search continues. Circulation 2007; 116: 131-133.
8 Graff J, von Hentig N, Misselwitz F. et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombi-nase activity. J Clin Pharmacol 2007; 47: 1398-1407.
9 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 204S-233S.
10 Francis CW. New issues in oral anticoagulants. Hematology 2008: 259-265.
11 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
12 Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and phar-macokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinetics 2009; 48: 1-22.
13 Turpie AG, Lassen MR, Eriksson BI. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
14 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31: 326-343.
15 Turpie AG, Bauer KA, Eriksson BI. et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
16 Huang J, Cao Y, Liao C. et al. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2011; 105: 245-253.
17 Raskob G, Cohen AT, Eriksson BI. et al. Oral direct factor Xa inhibition with ed-oxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010; 104: 642-649.
18 Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29: 155-165.
19 Iwatsuki Y, Sato T, Moritani Y. et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol 2011; 673: 49-55.
20 Hashimoto T, Suzuki K, Kihara Y. et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica 2013; 43: 534-547.
21 Groenendaal-van de Meent D, Heeringa M, Kadokura T. et al. YM150, an oral direct inhibitor of factor Xa, demonstrated a predictable and dose-proportional pharmacokinetic/pharmacodynamic profile after single and multiple dosing: Results from three studies (Abstract). Blood 2010; 116: 332.
22 Eriksson BI, Turpie AG, Lassen MR. et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5: 1660-1665.
23 Eriksson BI, Turpie AG, Lassen MR. et al. Prevention of venous thromboembol-ism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010; 8: 714-721.
24 Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembol-ism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study. Thromb Res 2012; 130: e52-59.
25 Fuji T, Nakamura M, Takeuchi M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: Results from 2 randomized, placebo-controlled, double-blind studies. Clin Appl Thromb Hemost. 2012 epub ahead of print.
26 Kimmel SE, Chen Z, Price M. et al. The influence of patient adherence on anti-coagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Int Med 2007; 167: 229-235.
27 van der Meer FJ, Briet E, Vandenbroucke JP. et al. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997; 98: 893-900.
28 Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Canad J Cardiol 2013; 29 (Suppl. 07) S24-33.
29 Bellamy L, Rosencher N, Eriksson B. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Pref Adherence 2009; 3: 173-177.
30 Cramer JA, Mattson RH, Prevey ML. et al. How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 1989; 261: 3273-3277.
31 Pullar T, Birtwell AJ, Wiles PG. et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Therap 1988; 44: 540-545.
32 Bristol-Myers Squibb.. Eliquis (Apixaban) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed July 1, 2013.
33 Bayer.. Xarelto (Rivaroxaban) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed July 1, 2013.
34 Haas S. Rivaroxaban – an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009; 82: 339-349.
35 Kubitza D, Becka M, Wensing G. et al. Safety, pharmacodynamics, and pharma-cokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
36 Eriksson BI, Borris L, Dahl OE. et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
37 Eriksson BI, Borris LC, Dahl OE. et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
38 Frost C, Nepal S, Wang J. et al. Safety, pharmacokinetics and pharmacody-namics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013 epub ahead of print.
39 Botticelli Investigators Writing Committee. Buller H, Deitchman D. et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
40 ClinicalTrials.gov.. Available at: http://clinicaltrials.gov/ct2/show/NCT00902928. Last accessed February 2013.
41 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144.
42 Kalebo P, Anthmyr BA, Eriksson BI. et al. Optimisation of ascending phle-bography of the leg for screening of deep vein thrombosis in thromboprophy-lactic trials. Acta Radiol 1997; 38: 320-326.
43 Groenendaal D, Kadokura T, Andersen G. et al. The pharmacokinetics of YM150, an oral direct factor Xa inhibitor, exhibits dose proportionality with no clinically relevant effect of ethnicity or gender. Clin Pharmacol Therapeut. 2011 89. (Suppl 1): Abstract PIII-59.
44 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
45 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharma-codynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Hae-most 2008; 100: 453-461.
46 Lassen MR, Davidson BL, Gallus A. et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
47 Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop 2008; 32: 443-451.
48 Lassen MR. Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. J Thromb Haemost 2009; 7: 889-891.
49 Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML. et al. Dabigatran, riva-roxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. Br Med J 2012; 344: e3675
50 Albertsen IE, Larsen TB, Rasmussen LH. et al. Prevention of venous throm-boembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. Drugs 2012; 72: 1755-1764.
51 Hirsh J, Guyatt G, Albers GW. et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8th Edition) Chest 2008; 133 (Suppl. 06) 71S-109S.
52 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxapa-rin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
53 Friedman RJ, Dahl OE, Rosencher N. et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010; 126: 175-182.
54 Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
55 Turpie AG, Lassen MR, Davidson BL. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
56 Kakkar AK, Brenner B, Dahl OE. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.

Zusatzmaterial

Zusatzmaterial